Juha Ranti

Long term follow-up of MRD guided treatment of Ibrutinib plus Venetoclax for Relapsed CLL: phase 2 VISION/HO141 trial (2025)

Blood Advances

Niemann, Carsten Utoft; Dubois, Julie; Nasserinejad, Kazem; da Cunha-Bang, Caspar; Kersting, Sabina; Enggaard, Lisbeth; Veldhuis, Gerrit-Jan; Mous, Rogier; Mellink, Clemens H.M.; van der Kevie-Kersemaekers, Anne-Marie F.; Dobber, Johan A.; Bjørn Poulsen, Christian; Razawy, Wida; Hollestein, Rene; Frederiksen, Henrik; Janssens, Ann; Schjødt, Ida; Dompeling, Ellen C.; Ranti, Juha; Brieghel, Christian; Mattsson, Mattias; Bellido, Mar; Tran, Hoa T.T.; Kater, Arnon P.; Levin, Mark-David

(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )

Real-world study on patient characteristics, treatment patterns and outcomes for treated patients with chronic lymphocytic leukemia during 2013–2022 in Finland (2025)

Annals of Hematology

Ranti, Juha; Jamalzadeh, Sanaz; Mäkelä, Eleonora; Vikkula, Johanna; Havula, Essi; Luopajärvi, Sari; Lindström, Vesa

(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )

Treatment and clinical outcomes of patients with acute myeloid leukemia in Finland 2010-2020: A retrospective analysis of electronic health records (2024)

European Journal of Haematology

Ranti, Juha; Pudas, Hanna; Ranta, Martta; Tuominen, Samuli; Uusi-Rauva, Kristiina; Lammela, Johanna

(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )

Ohjelmoituneen solukuoleman muokkaajat leukemioissa (2024)

Duodecim

Kuusanmäki, Heikki; Ranti, Juha; Kontro, Mika

(A2 Vertaisarvioitu katsausartikkeli tieteellisessä lehdessä)

Prolonged viral pneumonia and high mortality in COVID-19 patients on anti-CD20 monoclonal antibody therapy (2024)

European Journal of Clinical Microbiology and Infectious Diseases

Feuth Eeva, Nieminen Valtteri, Palomäki Antti, Ranti Juha, Sucksdorff Marcus, Finnilä Taru, Oksi Jarmo, Vuorinen Tytti, Feuth Thijs

(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )

Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial (2022)

Lancet Oncology

Kater Arnon P., Levin Mark-David, Dubois Julie, Kersting Sabina, Enggaard Lisbeth, Veldhuis Gerrit J., Mous Rogier, Mellink Clemens H.M., van der Kevie-Kersemaekers Anne-Marie F., Dobber Johan A., Poulsen Christian B., Frederiksen Henrik, Janssens Ann, Schjødt Ida, Dompeling Ellen C., Ranti Juha, Brieghel Christian, Mattsson Mattias, Bellido Mar, Tran Hoa T.T., Nasserinejad Kazem, Niemann Carsten U.

(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))

Clinical and healthcare burden of disease associated with cytomegalovirus in allogeneic hematopoietic stem cell transplantation - A retrospective single-center study (2022)

Transplant Infectious Disease

Ranti Juha, Perkonoja Katariina, Kauko Tommi, Korhonen Riku

(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))

Characterization of real-world treatment practices and outcomes among patients with chronic lymphocytic leukemia treated in a Finnish tertiary center (2021)

eJHaem - eJournal of Haematology

Ranti Juha, Perkonoja Katariina, Kauko Tommi, Loponen Heidi, Joensuu Emmi I., Järvinen Tiina M.

(Vertaisarvioitu katsausartikkeli tieteellisessä aikakauslehdessä (A2))

Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (2021)

Blood

Niemann CU, Levin MD, Dubois J, Kersting S, Enggaard L, Veldhuis GJ, Mous R, Mellink CHM, Dobber JA, Poulsen CB, Frederiksen H, Janssens A, Schjødt I, Dompeling EC, Ranti J, Bellido M, Mattsson M, Nasserinejad K, Tran HTT, Kater AP

(Kirjoitus tai data-artikkeli tieteellisessä aikakauslehdessä (B1))

Protocol description of the HOVON 141/VISION trial: a prospective, multicentre, randomised phase II trial of ibrutinib plus venetoclax in patients with creatinine clearance >= 30 mL/min who have relapsed or refractory chronic lymphocytic leukaemia (RR-CLL) with or without TP53 aberrations (2020)

BMJ Open

Levin Mark-David, Kater Arnon P, Mattsson Mattias, Kersting Sabina, Ranti Juha, Tran Hoa Thi Tuyet, Nasserinejad Kazem, Niemann Carsten Utoft

(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))

Juha

Ranti

Ota yhteyttä

Asiantuntijuusalueet

Julkaisut

Järjestä:

Long term follow-up of MRD guided treatment of Ibrutinib plus Venetoclax for Relapsed CLL: phase 2 VISION/HO141 trial (2025)

Real-world study on patient characteristics, treatment patterns and outcomes for treated patients with chronic lymphocytic leukemia during 2013–2022 in Finland (2025)

Treatment and clinical outcomes of patients with acute myeloid leukemia in Finland 2010-2020: A retrospective analysis of electronic health records (2024)

Ohjelmoituneen solukuoleman muokkaajat leukemioissa (2024)

Prolonged viral pneumonia and high mortality in COVID-19 patients on anti-CD20 monoclonal antibody therapy (2024)

Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial (2022)

Clinical and healthcare burden of disease associated with cytomegalovirus in allogeneic hematopoietic stem cell transplantation - A retrospective single-center study (2022)

Characterization of real-world treatment practices and outcomes among patients with chronic lymphocytic leukemia treated in a Finnish tertiary center (2021)

Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (2021)

Protocol description of the HOVON 141/VISION trial: a prospective, multicentre, randomised phase II trial of ibrutinib plus venetoclax in patients with creatinine clearance >= 30 mL/min who have relapsed or refractory chronic lymphocytic leukaemia (RR-CLL) with or without TP53 aberrations (2020)